207 related articles for article (PubMed ID: 17210670)
21. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
[TBL] [Abstract][Full Text] [Related]
22. Selective methylation of CpGs at regulatory binding sites controls NNAT expression in Wilms tumors.
Hubertus J; Zitzmann F; Trippel F; Müller-Höcker J; Stehr M; von Schweinitz D; Kappler R
PLoS One; 2013; 8(6):e67605. PubMed ID: 23825673
[TBL] [Abstract][Full Text] [Related]
23. Imbalanced expression of functionally different WT1 isoforms may contribute to sporadic unilateral Wilms' tumor.
Liu JJ; Wang ZY; Deuel TF; Xu YH
Biochem Biophys Res Commun; 1999 Jan; 254(1):197-9. PubMed ID: 9920757
[TBL] [Abstract][Full Text] [Related]
24. Control of epigenetic states by WT1 via regulation of de novo DNA methyltransferase 3A.
Szemes M; Dallosso AR; Melegh Z; Curry T; Li Y; Rivers C; Uney J; Mägdefrau AS; Schwiderski K; Park JH; Brown KW; Shandilya J; Roberts SG; Malik K
Hum Mol Genet; 2013 Jan; 22(1):74-83. PubMed ID: 23042785
[TBL] [Abstract][Full Text] [Related]
25. Wilms' tumor-specific methylation pattern in 11p13 detected by PFGE.
Royer-Pokora B; Schneider S
Genes Chromosomes Cancer; 1992 Sep; 5(2):132-40. PubMed ID: 1381949
[TBL] [Abstract][Full Text] [Related]
26. Expression of the 11p13 Wilms' tumor gene, WT1, correlates with histologic category of Wilms' tumor.
Gerald WL; Gramling TS; Sens DA; Garvin AJ
Am J Pathol; 1992 May; 140(5):1031-7. PubMed ID: 1316081
[TBL] [Abstract][Full Text] [Related]
27. Altered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor.
Park S; Tomlinson G; Nisen P; Haber DA
Cancer Res; 1993 Oct; 53(20):4757-60. PubMed ID: 8402654
[TBL] [Abstract][Full Text] [Related]
28. Wilms tumour histology is determined by distinct types of precursor lesions and not epigenetic changes.
Fukuzawa R; Anaka MR; Heathcott RW; McNoe LA; Morison IM; Perlman EJ; Reeve AE
J Pathol; 2008 Aug; 215(4):377-87. PubMed ID: 18484682
[TBL] [Abstract][Full Text] [Related]
29. Role of the WT1 gene in Wilms' tumour.
Haber DA; Housman DE
Cancer Surv; 1992; 12():105-17. PubMed ID: 1322241
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour.
Astuti D; Latif F; Wagner K; Gentle D; Cooper WN; Catchpoole D; Grundy R; Ferguson-Smith AC; Maher ER
Br J Cancer; 2005 Apr; 92(8):1574-80. PubMed ID: 15798773
[TBL] [Abstract][Full Text] [Related]
31. The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor.
Shimamura R; Fraizer GC; Trapman J; Lau YfC ; Saunders GF
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2571-80. PubMed ID: 9815658
[TBL] [Abstract][Full Text] [Related]
32. CTCF binding at the H19 imprinting control region mediates maternally inherited higher-order chromatin conformation to restrict enhancer access to Igf2.
Kurukuti S; Tiwari VK; Tavoosidana G; Pugacheva E; Murrell A; Zhao Z; Lobanenkov V; Reik W; Ohlsson R
Proc Natl Acad Sci U S A; 2006 Jul; 103(28):10684-9. PubMed ID: 16815976
[TBL] [Abstract][Full Text] [Related]
33. Methylation changes in promoter and enhancer regions of the WT1 gene in Wilms' tumours.
Mares J; Kríz V; Weinhäusel A; Vodicková S; Kodet R; Haas OA; Sedlácek Z; Goetz P
Cancer Lett; 2001 May; 166(2):165-71. PubMed ID: 11311489
[TBL] [Abstract][Full Text] [Related]
34. Wilms' tumour--a case of disrupted development.
Miyagawa K; Kent J; Schedl A; van Heyningen V; Hastie ND
J Cell Sci Suppl; 1994; 18():1-5. PubMed ID: 7883783
[TBL] [Abstract][Full Text] [Related]
35. Increased expression of the insulin-like growth factor-II gene in Wilms' tumor is not dependent on loss of genomic imprinting or loss of heterozygosity.
Wang WH; Duan JX; Vu TH; Hoffman AR
J Biol Chem; 1996 Nov; 271(44):27863-70. PubMed ID: 8910385
[TBL] [Abstract][Full Text] [Related]
36. Correlations between histological characterizations and methylation statuses of tumour suppressor genes in Wilms' tumours.
Lai YC; Lu MY; Wang WC; Hou TC; Kuo CY
Int J Exp Pathol; 2022 Jun; 103(3):121-128. PubMed ID: 35436013
[TBL] [Abstract][Full Text] [Related]
37. Relationship of porcine IGF2 imprinting status to DNA methylation at the H19 DMD and the IGF2 DMRs 1 and 2.
Braunschweig MH; Owczarek-Lipska M; Stahlberger-Saitbekova N
BMC Genet; 2011 May; 12():47. PubMed ID: 21575277
[TBL] [Abstract][Full Text] [Related]
38. [Wilms' tumors and malformation complexes].
Hata J; Fukuzawa R; Takata A; Kikuchi H
Nihon Rinsho; 2000 Jul; 58(7):1419-25. PubMed ID: 10921316
[TBL] [Abstract][Full Text] [Related]
39. Mutation of a single CTCF target site within the H19 imprinting control region leads to loss of Igf2 imprinting and complex patterns of de novo methylation upon maternal inheritance.
Pant V; Kurukuti S; Pugacheva E; Shamsuddin S; Mariano P; Renkawitz R; Klenova E; Lobanenkov V; Ohlsson R
Mol Cell Biol; 2004 Apr; 24(8):3497-504. PubMed ID: 15060168
[TBL] [Abstract][Full Text] [Related]
40. Abnormal RNA expression of 11p15 imprinted genes and kidney developmental genes in Wilms' tumor.
Schwienbacher C; Angioni A; Scelfo R; Veronese A; Calin GA; Massazza G; Hatada I; Barbanti-Brodano G; Negrini M
Cancer Res; 2000 Mar; 60(6):1521-5. PubMed ID: 10749116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
